Day One Biopharma Shares Rise on Ojemda Sales Outlook

Dow Jones

昨天

By Elias Schisgall

Shares of Day One Biopharmaceuticals rose after the company said it is projecting 53% growth in sales of Ojemda, a treatment for relapsed or refractory pediatric low-grade glioma.

Shares were recently up 21% at $10.81 in Monday morning trading. The stock has fallen 5% in the past year.

Day One said Sunday that Ojemda brought in $52.8 million of sales during the fourth quarter and $155.4 million for the full year, representing 172% year-over-year growth compared with 2024.

It said it anticipates sales in 2026 between $225 million and $250 million, which would represent 53% year-over-year growth at the midpoint.

The company added that it hopes to see Ojemda adopted as standard of care and expand sales of the treatment internationally via an international partner.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 12, 2026 09:48 ET (14:48 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2602549368"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602549368\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602549368?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602549368","market":"fut","top_or_hot":-1,"title":"Day One Biopharma Shares Rise on Ojemda Sales Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals</a> rose after the company said it is projecting 53% growth in sales of Ojemda, a treatment for relapsed or refractory pediatric low-grade glioma. \n</p>\n<p>\n  Shares were recently up 21% at $10.81 in Monday morning trading. The stock has fallen 5% in the past year. \n</p>\n<p>\n  Day One said Sunday that Ojemda brought in $52.8 million of sales during the fourth quarter and $155.4 million for the full year, representing 172% year-over-year growth compared with 2024. \n</p>\n<p>\n  It said it anticipates sales in 2026 between $225 million and $250 million, which would represent 53% year-over-year growth at the midpoint. \n</p>\n<p>\n  The company added that it hopes to see Ojemda adopted as standard of care and expand sales of the treatment internationally via an international partner. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 09:48 ET (14:48 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Day One Biopharma Shares Rise on Ojemda Sales Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDay One Biopharma Shares Rise on Ojemda Sales Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-12 22:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals</a> rose after the company said it is projecting 53% growth in sales of Ojemda, a treatment for relapsed or refractory pediatric low-grade glioma. \n</p>\n<p>\n  Shares were recently up 21% at $10.81 in Monday morning trading. The stock has fallen 5% in the past year. \n</p>\n<p>\n  Day One said Sunday that Ojemda brought in $52.8 million of sales during the fourth quarter and $155.4 million for the full year, representing 172% year-over-year growth compared with 2024. \n</p>\n<p>\n  It said it anticipates sales in 2026 between $225 million and $250 million, which would represent 53% year-over-year growth at the midpoint. \n</p>\n<p>\n  The company added that it hopes to see Ojemda adopted as standard of care and expand sales of the treatment internationally via an international partner. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 09:48 ET (14:48 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602549368","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602549368","pubTimestamp":1768229280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Day One Biopharmaceuticals rose after the company said it is projecting 53% growth in sales of Ojemda, a treatment for relapsed or refractory pediatric low-grade glioma.Shares were recently up 21% at $10.81 in Monday morning trading. The stock has fallen 5% in the past year.Day One said Sunday that Ojemda brought in $52.8 million of sales during the fourth quarter and $155.4 million for the full year, representing 172% year-over-year growth compared with 2024.It said it anticipates sales in 2026 between $225 million and $250 million, which would represent 53% year-over-year growth at the midpoint.The company added that it hopes to see Ojemda adopted as standard of care and expand sales of the treatment internationally via an international partner.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","DAWN":"Day One Biopharmaceuticals Inc."},"translate_title":"第一天生物制药股价因Ojemda销售前景而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DAWN":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Day One Biopharmaceuticals rose after the company said it is projecting 53% growth in sales of Ojemda, a treatment for relapsed or refractory pediatric low-grade glioma. \n\n\n  Shares were recently up 21% at $10.81 in Monday morning trading. The stock has fallen 5% in the past year. \n\n\n  Day One said Sunday that Ojemda brought in $52.8 million of sales during the fourth quarter and $155.4 million for the full year, representing 172% year-over-year growth compared with 2024. \n\n\n  It said it anticipates sales in 2026 between $225 million and $250 million, which would represent 53% year-over-year growth at the midpoint. \n\n\n  The company added that it hopes to see Ojemda adopted as standard of care and expand sales of the treatment internationally via an international partner. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 09:48 ET (14:48 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}